Patients taking GLP-1 weight-loss drugs such as Zepbound and Mounjaro are reporting sharper smell perception and, in some cases, intense new interest in perfume rather than food.
Doctors say the pattern appears tied to reduced food reward: as eating becomes less stimulating, scents and other sensory experiences may feel more noticeable or rewarding.
Todd Masterson said 14 months on Zepbound left him nearly 80 pounds lighter and with a fragrance collection approaching 100 bottles; other users describe vanilla-heavy scents becoming newly appealing.
Researchers say GLP-1 receptors in the olfactory bulb and hippocampus could help explain altered odor processing, while FDA adverse-event data also include reports of parosmia—smell distortions that can make food odors unpleasant.
Large controlled studies have not yet tested the phenomenon, leaving the perfume link anecdotal even as users and some clinicians report a recurring shift in scent sensitivity.
With GLP-1 drugs acting on the brain’s smell center, have we found a new way to control addiction?
If a diet drug can create a perfume boom, what other consumer markets will it unexpectedly transform next?
As weight-loss drugs rewire our sense of smell, what other core desires are being secretly reshaped?